Amphastar Pharmaceuticals (NASDAQ: AMPH) is one of 116 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Amphastar Pharmaceuticals to similar companies based on the strength of its institutional ownership, earnings, analyst recommendations, valuation, risk, dividends and profitability.


This table compares Amphastar Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Amphastar Pharmaceuticals 1.61% 2.42% 1.84%
Amphastar Pharmaceuticals Competitors -2,859.71% -67.96% -9.24%

Analyst Ratings

This is a summary of recent ratings and target prices for Amphastar Pharmaceuticals and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amphastar Pharmaceuticals 0 1 5 0 2.83
Amphastar Pharmaceuticals Competitors 840 3776 6801 185 2.55

Amphastar Pharmaceuticals currently has a consensus price target of $20.17, indicating a potential upside of 11.11%. As a group, “Pharmaceuticals” companies have a potential upside of 24.82%. Given Amphastar Pharmaceuticals’ rivals higher possible upside, analysts clearly believe Amphastar Pharmaceuticals has less favorable growth aspects than its rivals.

Valuation & Earnings

This table compares Amphastar Pharmaceuticals and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Amphastar Pharmaceuticals $249.62 million $17.41 million 226.90
Amphastar Pharmaceuticals Competitors $8.20 billion $2.68 billion -1.59

Amphastar Pharmaceuticals’ rivals have higher revenue and earnings than Amphastar Pharmaceuticals. Amphastar Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Volatility and Risk

Amphastar Pharmaceuticals has a beta of 1.69, meaning that its share price is 69% more volatile than the S&P 500. Comparatively, Amphastar Pharmaceuticals’ rivals have a beta of 0.89, meaning that their average share price is 11% less volatile than the S&P 500.

Institutional & Insider Ownership

44.0% of Amphastar Pharmaceuticals shares are held by institutional investors. Comparatively, 44.3% of shares of all “Pharmaceuticals” companies are held by institutional investors. 11.1% of Amphastar Pharmaceuticals shares are held by insiders. Comparatively, 12.0% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.


Amphastar Pharmaceuticals beats its rivals on 7 of the 13 factors compared.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, Cortrosyn, Amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin. The Company also manufactures and sells insulin API. As of December 31, 2016, the Company manufactured and sold 19 products. As of December 31, 2016, the Company developed a portfolio of 15 generic abbreviated new drug applications (ANDAs) three generic biosimilar product candidates and six injectable and inhalation product candidates.

Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.